3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

Bristol Myers Squibb trades at a low P/E ratio of 9 despite a 42.5% stock surge over the past year, reflecting investor uncertainty about its ability to offset major patent expirations. However, the company's strong growth portfolio (up 15%) and new drug launches suggest successful patent cliff mitigation, potentially offering upside if 2027-2028 results exceed expectations.